Pembrolizumab and Nab Paclitaxel in Patients With Metastatic Urothelial Carcinoma

Summary

This phase II, single-center study will assess the efficacy of pembrolizumab + nab-paclitaxel in patients who have metastatic urothelial tumor and do not respond to chemotherapy. The time between drug administration and progression of the disease will be assessed to determine if the drug will work.

Timeline

Start

2019-01-16

Primary completion

2020-01-21

Completion

2020-01-21

Publications

• Giannatempo P, Raggi D, Marandino L, Bandini M, Fare E, Calareso G, Colecchia M, Gallina A, Ross JS, Alessi A, Briganti A, Montorsi F, Madison R, Necchi A. Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma: interim results of the open-label, single-arm, phase II PEANUT study. Ann Oncol. 2020 Dec;31(12):1764-1772. doi: 10.1016/j.annonc.2020.09.012. Epub 2020 Sep 23.

Drugs

Indications